Citi: Initiates 90-day catalyst observation period for INNOVENT BIO (01801) with a target price of HK$62.

09:48 12/09/2024

Citibank expects that with the drive of new products, Sinda Bio's strong growth momentum will continue.

Citibank released a research report stating that they have started a 90-day catalyst observation period for INNOVENT BIO (01801). The bank expects that with the drive of new products, the strong growth momentum of INNOVENT BIO will continue. Taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/IBI112 (IL-23 p19) are expected to be approved in the second half of this year or next year. The target price is 62 Hong Kong dollars, with a rating of "buy/high risk".

ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.

CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.

NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.

ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.

CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.

NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.